Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients

Manuela Ferrario^a Jochen G. Raimann^b Brett Larive^c Andreas Pierratos^d
Stephan Thijssen^b Sanjay Rajagopalan^e Tom Greene^f Sergio Cerutti^a
Gerald Beck^c Christopher Chan^d Peter Kotanko^{b, g} the Frequent
Hemodialysis Network (FHN) Trial Group

^aPolitecnico di Milano, Department of Electronics, Information and Bioengineering (DEIB), Milano, Italy;

^bRenal Research Institute, New York City, N.Y., and ^cCleveland Clinic Foundation, Cleveland, Ill., USA; ^dUniversity Health Network, Toronto, Canada; ^eOhio State University, Columbus, Ohio, ^fUniversity of Utah, Salt Lake City, Utah, and ^gIcahn School of Medicine at Mount Sinai, New York City, N.Y., USA

Key Words

Cardiac function · Cardiac MRI · Fluid status · Hemodialysis · Heart rate variability

Abstract

Background: Non-linear heart rate variability (HRV) indices were hypothesized to correlate with cardiac function, fluid overload and physical performance in hemodialysis patients. **Methods:** Twenty-four-hour Holter electrocardiograms were recorded in patients enrolled in the Frequent Hemodialysis Network (FHN) Daily Dialysis Trial. Correlations between non-linear HRV indices and left ventricular ejection fraction (LVEF), left ventricular end-diastolic volume (LVEDV), extracellular volume (ECV)/total body water (TBW) ratio, the SF-36 Physical Health Composite (PHC) and Physical Functioning (PF) scores were tested. **Results:** We studied 210 subjects (average age 49.8 ± 13.5 years, 62% men, 42% diabetics). In non-diabetic patients, multiscale entropy (MSE) slope sample entropy (SampEn) and approximate entropy (ApEn) correlated positively with LVEF, PF and PHC and inversely

with LVEDV and ECV/TBW. Spectral power slope correlated positively with ECV/TBW ($r = 0.27$). Irregularity measures (MSE ApEn and MSE SampEn) correlated positively with LVEDV ($r = 0.19$ and 0.20). **Conclusion:** Non-linear HRV indices indicated an association between a deteriorated heart rate regulatory system and impaired cardiac function, fluid accumulation and poor physical condition.

© 2015 S. Karger AG, Basel

Introduction

Cardiovascular disease is the leading cause of death in hemodialysis (HD) patients. Left ventricular hypertrophy (LVH) and left ventricular dilatation, both conditions commonly diagnosed by either MRI [1] or echocardiography [2], are present in a substantial fraction of HD patients primarily due to salt and volume overload [3, 4]. LVH has been shown to be associated with outcomes in dialysis patients [2]. Chronic and acute inflammation [5], anemia [6], high blood pressure [7], elevated levels of

fibroblast growth factor-23 [8, 9] and myocardial hypoperfusion [10, 11] during HD have been shown to be associated with left ventricular function and LVH [5, 12]. Besides structural cardiac abnormalities, reduced left ventricular ejection fraction (LVEF) has also been reported in a substantial percentage of HD patients [13–15].

Disturbances of autonomic control of heart rate are common among HD patients, with sympathetic overactivity being the principal alteration [16, 17]. Cardiac autonomic function can be characterized through the analysis of the variability of the so-called RR time series, that is, the series of time intervals between consecutive R peaks (heart beats; RR intervals) measured by electrocardiogram (ECG).

Non-linear methods were proposed to investigate the heart rate variability (HRV) regulatory system from a more complex perspective. HRV is the result of a complex regulatory system related to the electrical depolarization of cardiac cells, which is primarily regulated by (1) the autonomic nervous system (2) the mechanical and functional properties of cardiac cells and (3) electrolytes acting on the refractory period of the action potential in the cardiac cells. Non-linear methods were proposed to characterize these properties of the cardiac regulatory system quantitatively from one of its measures, that is, the heart rate [18].

Certain pathological conditions and aging are defined by the loss of complexity in the dynamics of the heart rate regulatory system [19]. In particular, diabetic patients often suffer from cardiovascular autonomic neuropathy, a pathology characterized generally by a reduced HRV.

In the general population, non-linear HRV indices are established to provide additional information to 'traditional' HRV indices and improve the ability to identify patients at high risk of cardiovascular death [19–21]. The diagnostic advantages of non-linear HRV indices suggest that they capture unique information. Comparisons of non-linear HRV measures between HD and healthy subjects [22–25] have so far focused on their prognostic value.

In this work, we hypothesized non-linear HRV indices would correlate cross-sectionally with cardiac function, fluid overload and physical performance, and we examined correlations using all the subjects and also separately by diabetic status. To that end, we characterized non-linear HRV measures in a large cohort of HD patients and explored their correlations with left ventricular mass (LVM), left ventricular end-diastolic volume (LVEDV), LVEF, extracellular volume (ECV)/total body water (TBW) ratio and self-reported physical performance.

Patients and Methods

Frequent Hemodialysis Network Daily Trial

The Frequent Hemodialysis Network (FHN) Daily Dialysis Trial (ClinicalTrials.gov#NCT00264758) was a multicenter randomized trial comparing conventional thrice weekly HD with short 6× weekly in-center HD. Study design with inclusion and exclusion criteria was described previously [26]. Patients were enrolled between March 2006 and May 2009, and the trial concluded in May 2010. The study was conducted in accordance with the Declaration of Helsinki and approved by the institutional review board at each participating site. An independent Data Safety Monitoring Board provided oversight of the trial.

Measurements

We determined LVM, LVEDV and LVEF by cardiac MRI at baseline. All MRI images were analyzed centrally in a blinded manner. A detailed explanation of the MRI methodology was recently published [1]. Holter ECG was recorded by the study staff using the KCI X5 digital Holter recorder (KCI Technology and Services, N.J., USA). Systolic and diastolic blood pressures were measured before HD by an automated oscillometric method.

We determined TBW, ECV, intracellular volume (ICV), phase angle and lean body mass based on anthropometric measures and single frequency (50 kHz) whole body bioimpedance analysis (BIA; RJL Systems, Clinton Township, N.J., USA). TBW and total body potassium content were calculated using polynomial regression modeling of bioimpedance-derived data [27]. ECV was calculated as the difference between TBW and ICV. Accuracy and precision of this BIA method was recently reported [28]. Residual renal urea clearance was determined based on 24-hour urine samples. The Physical Health Composite (PHC) and the Physical Functioning (PF) scores were assessed using the RAND short form (SF)-36 survey [29].

HRV Analysis

R-R time series were extracted from 24-hour Holter ECG recordings. QRS complexes were detected and classified with the Holter software CubeHolter (Cardioline S.p.A, Italy). Holter recordings shorter than 15 hours were excluded from subsequent analyses. Differences in time length may affect the estimation of long-term correlation indices, as well as artifacts (noise, detachment of electrodes, etc.) [30].

ECG recordings can be corrupted by noise, which results in a failure of automatic classification system to detect the actual heart beat duration and is labeled as an unreliable measure (artifact). From the RR time series with sufficient length and less than 5% of RR intervals classified as artifacts, we measured the following non-linear indices: the slope of the de-trended fluctuation analysis (DFA) estimated with a linear de-trend and with a quadratic de-trend, the slope of the power spectrum at very low frequencies (spectral power slope (SPS)), the slope from the multiscale entropy (MSE) measured with two different entropy estimators (the approximate entropy (ApEn) and the sample entropy (SampEn)) and a global index of regularity estimated as the entropy value of the entire recording (ApEn and SampEn). Technical details are illustrated in the appendix.

Statistical Analyses

Descriptive statistics for continuous variables were summarized using mean $\pm$ SD or medians and 10th and 90th percentiles as appropriate. Categorical variables were summarized using fre-

Table 1. Subject characteristics at enrollment for FHN patients with available data for non-linear HRV indices

Variables	ALL (n = 210)		D (n = 85)		ND (n = 118)	
	n	mean ± SD or n (%)	n	mean ± SD or n (%)	n	mean ± SD or n (%)
Age, years	210	49.8±13.5	85	55.4±12.3[§]	118	45.8±13.1
Male	210	130 (62)	85	50 (59)	118	76 (64)
Diabetes	203	85 (42)	–	73 (41)	27	12 (44)
Pre-dialysis albumin, per 0.1 g/dl	206	39.3±4.0	85	38.3±3.6*	117	40.1±4.0
Pre-dialysis phosphorus, mg/dl	206					
<5.5		98 (48)		39 (46)		56 (48)
≥5.5 and <7.0		65 (32)		27 (32)		37 (32)
≥7.0		43 (21)	85	19 (22)	117	24 (21)
Hemoglobin, g/dl	198	11.9±1.3	82	11.8±1.3	112	12.0±1.4
Residual renal clearance, ml/min	204					
0		127 (62)		50 (59)		77 (66)
>0 and ≤0.8		22 (11)		10 (12)		12 (10)
>0.8 and <1.4		20 (10)		9 (11)		11 (9)
>1.4		35 (17)	85	16 (19)	117	17 (15)
Weekly enPCR, g/kg/day	204	10.6±2.8	85	10.8±2.9	117	10.4±2.7
eKt/V	204	1.42±0.25	85	1.40±0.26	117	1.45±0.24
Left ventricular mass, g	177	146±59	74	142±49	103	149±64
LVEDV, ml	177	182±64	74	174±52	103	188±71
LVEF, %	177	56.7±11.2	74	54.5±13.0[#]	103	58.3±9.6
Heart rate as measured centrally, bpm	177	75.9±13.9	74	75.9±12.6	103	75.9±14.8
Urine volume, l	210		85		118	
0		151 (72)		58 (68)		86 (73)
>0 and ≤1		57 (27)		27 (32)		30 (25)
>1.0		2 (1)		0		2 (2)
ECV, l	193	22.9±4.7	80	24.5±4.7*	112	21.9±4.4
ECV/total body water	193	0.523±0.067	80	0.536±0.068[#]	112	0.513±0.065
Lean body mass	193	44.6±10.3	80	46.3±10.3	112	43.5±10.1
Ultrafiltration volume, l	206	3.33±1.20	85	3.60±1.23[#]	117	3.17±1.16
PHC (RAND SF36)	203	37.4±10.9	83	34.4±10.6*	115	39.6±10.7
PF scale (SF36)	204	55.9±27.4	84	44.8±26.6[§]	115	63.6±25.4
Short physical performance battery score	206	10.9±3.0	85	9.92±3.08[§]	117	11.6±2.8

Significant differences between diabetic and non-diabetic groups are shown in bold font: [§] p value ≤0.0001; * p value <0.005; [#] p value <0.05.

quencies and proportions. Demographic and non-linear HRV parameters were compared between diabetic and non-diabetic subjects using the Student's t test, the exact Wilcoxon signed rank test, the Chi-square or the Fisher exact test, as appropriate. The same comparisons were performed also between randomized and non-randomized patient for completeness.

We derived correlations between the non-linear HRV parameters and (1) cardiovascular (LVM and LVEDV), (2) fluid status (ECV/TBW) and (3) self-reported physical health (PHC and PF) measures, according to a predefined analysis plan. As demonstrated previously, about correlation with age and pathology progression [31, 32], we explored correlations with age and end-stage renal disease (ESRD) vintage also in our population. The significant correlation with self-reported physical health was further investigated with the correlation analysis among physical condition-related parameters (phase angle, lean body mass and ICV as assessed by BIA) as ancillary analyses. We examined correlations using all subjects (ALL) and separately by diabetic status (non-diabetics

(ND) and diabetics (D)). We depicted associations using scatter plots with separate local regression curves for diabetics and non-diabetics and also calculated Pearson's and Spearman's correlation coefficients based on subjective assessment of influential data points.

Two-tailed p values <0.05 were considered statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Cary, N.C., USA).

Results

We studied 210 patients with qualifying Holters, 176 of whom were eventually randomized into the FHN Daily Dialysis Trial. The subjects' baseline characteristics are illustrated in table 1. Furthermore, they did not differ

Table 2. Values of HRV indices at enrollment for FHN patients with available data for non-linear HRV indices

Variables	ALL (n = 210)		D (n = 85)		ND (n = 118)	
	n	mean ± SD	n	mean ± SD	n	mean ± SD
DFA	210	1.07±0.07	85	1.08±0.07	118	1.07±0.07
Quadratic DFA	210	1.05±0.07	85	1.05±0.08	118	1.05±0.07
SPS	210	1.32±0.22	85	1.40±0.22[§]	118	1.26±0.21
SampleEn (2, 0.15)	210	0.638±0.344	85	0.644±0.324	118	0.642±0.364
MSE slope SampEn	210	0.0088±0.0614	85	-0.014±0.060[#]	118	0.025±0.058
MSE slope ApEn	210	0.0099±0.0691	85	-0.019±0.065	118	0.030±0.066
ApEn (2, 0.15)	210	0.909±0.372	85	0.913±0.364	118	0.916±0.384
Percent deleted heart beats	210	4.47±5.87	85	5.06±7.29	118	4.15±4.76

Significant differences between diabetic and non-diabetic groups are shown in bold font: [§] p value ≤0.0001; [#] p value <0.05.

Table 3. Pearson and Spearman correlation coefficients for associations between HRV indices and measures related to heart functioning, fluid overload and physical condition for all subjects, and for non-diabetic and diabetic subjects

Measure characterization	Specific measures	Cohort	Long-term correlations			Complexity over different time scales		Irregularity	
			DFA	quadratic DFA	SPS	MSE slope ApEn	MSE slope SampEn	eApEn (2, 0.15) [†]	SampEn (2, 0.15) [†]
Heart functioning	LVEF, %	ALL	0.12	0.17*	0.05	0.27 [§]	0.25 [§]	-0.13	-0.09
		ND	0.17	0.18	0.10	0.26 [§]	0.23*	-0.11*	-0.02
		D	0.11	0.18	0.11	0.19	0.19	-0.15	-0.14
	LVEDV, ml	ALL	-0.10	-0.12	-0.12	-0.06	-0.06	0.12	0.11
		ND	-0.12	-0.15	-0.09	-0.20*	-0.20*	0.23*	0.22*
		D	-0.05	-0.07	-0.09	0.08	0.09	-0.04	-0.04
Fluid overload	ECV/TBW	ALL	0.13	0.08	0.23 [§]	-0.30 [§]	-0.29 [§]	-0.03	-0.03
		ND	0.16	0.13	0.25*	-0.33 [§]	-0.30 [§]	-0.06	-0.06
		D	0.07	0.02	0.12	-0.18	-0.20	0.02	0.00
Physical condition	PF scale (RAND SF-36)	ALL	-0.08	-0.04	-0.19*	0.30 [§]	0.30 [§]	0.00	0.05
		ND	-0.12	-0.10	-0.18	0.30 [§]	0.32 [§]	0.04	0.08
		D	-0.02	0.01	0.03	0.05	0.07	-0.01	0.03
	PHC (RAND SF-36)	ALL	0.01	0.01	-0.13	0.22 [§]	0.23 [§]	0.04	0.09
		ND	0.05	0.01	-0.09	0.22*	0.24*	0.00	0.03
		D	-0.04	-0.01	-0.01	0.03	0.06	0.13	0.16

[§] p value <0.01; * p value ≤0.05. [†] Associations for these HRV parameters were summarized with Spearman correlation coefficients. All other associations were summarized with Pearson correlation coefficients.

significantly between the patients who were eventually randomized (n = 176) and those who were not (n = 34). Table 2 reports the non-linear HRV parameters in the enrolled patients. The number of artifacts and unreliable RR intervals was 5% and deemed reasonable.

Cardiac MRI Parameters and HRV Indices

The two MSE slopes correlated significantly with LVEF by considering all patients and only non-diabetic patients. In non-diabetic patients, LVEDV correlated significantly with the two MSE slopes as well (table 3), and

Fig. 1. Scatter plot relating MSE slope ApEn and LVEF in diabetic ($r = 0.19$, n.s.) and non-diabetic ($r = 0.26$, $p < 0.01$) subjects is shown. Local regression curve are displayed.

Fig. 2. Scatter plot relating SPS and ECV/TBW in diabetic ($r = 0.12$, n.s.) and non-diabetic ($r = 0.25$, $p < 0.05$) subjects is shown. Local regression curve are displayed.

correlated positively with ApEn and SampEn. Figure 1 depicts the relationship between LVEF and the MSE ApEn (ALL $r = 0.27$, $p < 0.01$; ND $r = 0.26$, $p < 0.01$; D $r = 0.19$, n.s.). In diabetic subjects, no significant correlations were found (table 3).

Fluid Status and HRV Indices

ECW/TBW showed a positive correlation with the SPS (fig. 2), while it inversely correlated with MSE ApEn and MSE SampEn, both considering all patients and only non-diabetic patients. An inverse relationship between

Table 4. Correlation coefficients for associations between non-linear HRV indices and age and ESRD vintage for all subjects, and for non-diabetic and diabetic subjects

Measure characterization	Specific measures	Age			ESRD vintage		
		ALL	ND	D	ALL	ND	D
Long-term correlations	DFA	0.12	0.16	0.02	0.15	0.25*	0.03
	Quadratic DFA	0.04	0.10	-0.05	0.13	0.23*	-0.01
	SPS	0.37 [§]	0.39 [§]	0.13	-0.01	0.10	-0.07
Complexity over different time scales	MSE slope ApEn	-0.34 [§]	-0.34 [§]	-0.10	0.11	-0.03	0.24*
	MSE slope SampEn	-0.29 [§]	-0.34 [§]	0.00	0.09	-0.05	0.22*
Irregularity	ApEn (2, 0.15) [†]	0.16*	0.18*	0.19	-0.07	-0.04	-0.13
	SampEn (2, 0.15) [†]	0.09	0.13	0.09	-0.09	-0.07	-0.13

[§] p value <0.01; * p value ≤0.05. [†] Associations for these HRV parameters were summarized with Spearman correlation coefficients. All other associations were summarized with Pearson correlation coefficients.

Fig. 3. Scatter plot relating MSE slope ApEn and ECV/TBW in diabetic ($r = -0.18$, n.s.) and non-diabetic ($r = -0.33$, $p < 0.01$) subjects is shown. Local regression curve are displayed.

ECV/TBW and MSE SampEn was also present in diabetic subjects (table 3). Figure 3 depicts the relationship between ECV/TBW and MSE ApEn (ALL $r = -0.30$, $p < 0.01$; ND $r = -0.33$, $p < 0.01$; D $r = -0.18$, n.s.). In diabetic subjects, no significant correlations were found.

Physical Condition and HRV Indices

PF and PHC showed positive correlations with MSE slope ApEn and MSE slope SampEn in the entire population and in non-diabetic subjects, but not in diabetic

subjects (table 3). In particular, higher PF scores were associated with higher MSE slopes.

Non-linear HRV indices were also correlated with phase angle, lean body mass and ICV as assessed by BIA (table 4). Lean body mass showed significant inverse correlations with DFA and quadratic DFA in the entire population and in non-diabetic subjects and positive correlations with MSE slope ApEn and MSE slope SampEn in diabetic subjects (table 4). ICV associated inversely with DFA and quadratic DFA in the entire popu-

Table 5. Correlation coefficients for associations between non-linear HRV indices and parameters reflecting physical condition for all subjects, and for non-diabetic and diabetic subjects

Measure characterization	Specific measures	Parameters associated with physical condition								
		phase angle			lean body mass			ICV		
		ALL	ND	D	ALL	ND	D	ALL	ND	D
Long-term correlations	DFA	-0.17*	-0.18	-0.15	-0.21 [§]	-0.25*	-0.20	-0.21 [§]	-0.25*	-0.19
	Quadratic DFA	-0.10	-0.13	-0.09	-0.18*	-0.22*	-0.15	-0.17*	-0.21*	-0.13
	SPS	-0.12	-0.18*	-0.10	-0.04	-0.13	-0.07	-0.12	-0.18*	-0.10
Complexity over different time scales	MSE slope ApEn	0.25 [§]	0.31 [§]	0.16	0.12	0.15	0.26*	0.21 [§]	0.24*	0.26*
	MSE slope SampEn	0.23 [§]	0.29 [§]	0.15	0.17*	0.18	0.32 [§]	0.24 [§]	0.25*	0.31 [§]
Irregularity	ApEn (2, 0.15) [†]	0.02	-0.06	0.09	0.09	0.11	0.07	0.08	0.11	0.07
	SampEn (2, 0.15) [†]	0.02	-0.06	0.10	0.04	0.06	0.02	0.05	0.07	0.03

[§] p value <0.01; * p value ≤0.05. [†] Associations for these HRV parameters were summarized with Spearman correlation coefficients. All other associations were summarized with Pearson correlation coefficients.

lation and in non-diabetic subjects. Positive correlations were found between ICV and MSE slope ApEn and MSE slope SampEn for both diabetic and non-diabetic subjects (table 4). Finally, phase angle showed positive correlations with MSE slope ApEn and MSE slope SampEn (table 4).

Additional Correlations

Additional analyses of the relationships between non-linear HRV parameters and age and ESRD vintage, respectively, showed significant correlations (table 5). In non-diabetic subjects and for the entire population, age positively correlated with SPS and ApEn and inversely correlated with MSE slope ApEn and MSE slope SampEn (table 5). In non-diabetic subjects, DFA and quadratic DFA correlated positively with ESRD vintage, while in diabetic subjects only MSE slope ApEn and MSE slope SampEn correlated significantly with ESRD vintage (table 5).

Discussion

In this, to date, largest assessment of non-linear HRV parameters in HD patients, we characterized 210 of the FHN Daily Trial subjects. This allowed direct comparison to general population data and to individuals suffering with cardiac disease. We found significant correlations between non-linear HRV parameters

and (1) cardiac parameters, (2) biomarkers of fluid overload and (3) indicators of self-reported physical functioning.

Cross-Sectional Evaluation

The 210 HD patients showed an ApEn of 0.91 ± 0.37 , a DFA of 1.07 ± 0.07 and a power slope of 1.32 ± 0.22 (table 2). These values are comparable with values reported in the literature for other cardiovascular populations. Bigger et al. [20] reported a lower power slope of 1.06 ± 0.12 in 274 healthy subjects in the same age group. Pikkujämsä et al. [33] reported an ApEn of 1.01 ± 0.16 , a DFA long-term scaling exponent (α_2) of 1.07 ± 0.07 and a power slope of 1.32 ± 0.14 in 29 healthy 40- to 60-year-old subjects.

The trend of reduced HRV among those with more severe comorbid conditions is corroborated by increased power slope among patients with a myocardial infarction (power slope = 1.15 ± 0.19 (n = 715)) and those monitored after a cardiac transplant (power slope = 2.08 ± 0.22 (n = 19)) [20].

Earlier work in 54 HD patients by Fukuta et al. [22] showed a lower ApEn (0.93 ± 0.18) and a larger of DFA (α_2) 1.14 ± 0.07 with respect to that of healthy control subjects.

The comparison with literature suggests that the complexity loss of heart rate regulatory system is also present in ESRD, and it is associated to the worsening of cardiac function/pathology, this reinforces our hypothesis that non-linear HRV indices should have a similar relationship in HD population also.

Correlational Analysis

HD patients showed significant correlations between non-linear indices and cardiac MRI measures, fluid status and physical condition. MSE slope ApEn and MSE slope SampEn correlate positively with LVEF ($r = 0.26$ and $r = 0.23$, respectively) while both parameters correlated inversely with LVEDV. The directions of the trends are in agreement with the trend obtained by Costa et al. [34], where the majority of congestive heart failure patients had negative slopes on short scales. A reduced LVEF and an increased LVEDV are both signs of a compromised cardiac functionality. For example, a greater end-diastolic volume results in a greater distention of the ventricle, that is, an increase in preload. If such an abnormal condition prolongs for a long time, it can cause or contribute to the clinical syndrome of heart failure with a normal LVEF, namely diastolic heart failure [35]. Lombardi et al. [36] reported associations between linear and non-linear dynamics with LVEF.

We also found positive correlations between ApEn and SampEn with LVEDV, suggesting increased entropy with increased LVEDV. Similarly, fluid overload, quantified as ECV/TBW, showed an inverse relationship with MSE slope ApEn and MSE slope SampEn and a positive relationship with SPS (table 2). This is consistent with the study by Ferrario et al. [37] who showed decreased HRV entropy in fluid-overloaded subjects and with earlier work among congestive heart failure subjects whose condition may have resembled those affected by fluid overload [20, 38].

Age and HD vintage correlate with various HRV parameters (table 4). This coincides with earlier reports [20, 33, 39, 40] and reflects a progressive loss of entropy at older age (table 5). To the best of our knowledge, no data on the relationship between ESRD vintage and HRV have yet been reported. The reason for this loss of HRV remains speculative, but progressing uremic neuropathy [41] or consequences of longstanding repeated myocardial stunning [10] may be involved and could represent an exciting new field of study in the context of myocardial compromise during dialysis treatment.

To the best of our knowledge, relationships between non-linear HRV and self-reported physical functioning and indicators of body composition have not been explored previously. The positive relationships between MSE slope ApEn and MSE slope SampEn, respectively, and PF and PH, have the same trends as for LVEF and clearly underline the relevance of these parameters (table 4). Accordingly, the correlations between phase angle, lean body mass and ICV (a correlate of muscle mass) with the HRV parameters suggest the benefits of a good

nutritional status in this population where chronic inflammation and malnourishment is highly prevalent.

Our analysis of non-linear HRV indices supports an association between the worsening of the heart rate regulatory system and the worsening of cardiac function, fluid accumulation and physical condition. Furthermore, our data suggest these indices as useful parameters for decision support systems to identify worsening conditions of heart functionality and patients at elevated risk of death. We believe this will be a promising field of research in dialysis patients.

Acknowledgments

The authors wish to acknowledge and thank the entire FHN Trial Group. The data presented in this manuscript were not published in whole or in part.

Disclosure Statement

This work was supported by the National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), the Center for Medicare and Medical Services and the NIH Research Foundation. Contributors to the NIH Foundation in support of the FHN trials included Amgen, Baxter and Dialysis Clinics. Additional support was provided by DaVita, Dialysis Clinics, Fresenius Medical Care, Renal Advantage, Renal Research Institute and Satellite Healthcare.

Peter Kotanko holds stock in Fresenius Medical Care. All other authors have no conflict of interest to disclose.

Appendix

Non-Linear HRV Indices

Detrended Fluctuation Analysis

DFA can be interpreted as a modified root mean square analysis of a random walk [42]. The time series of the RR time interval is integrated and then divided into boxes of equal length, n . In each box, a least squares line is fit to the data or, in case of quadratic DFA, a least square quadratic trend. Next, the integrated time series is detrended by subtracting the local trend in each box and a root mean square fluctuation $F(n)$ is calculated over all time scales (box sizes) in order to characterize the relationship between the average fluctuation $F(n)$ and the box size n . A linear relationship on a log-log plot indicates the presence of power law (fractal) scaling. Under such conditions, the fluctuations can be characterized by a scaling exponent ν , the slope of the line relating $\log F(n)$ to $\log n$. In this work, two scaling exponents representing the long-term fluctuations ($n > 4$) are presented: the DFA and the quadratic DFA.

Spectral Power Slope

The R-R series was re-sampled at 2 Hz. The power spectrum was computed by Fourier Transform and a regression line was fitted on the very low frequencies between 0.0001 and 0.01 Hz.

SPS is strongly correlated to the DFA indices when a scaling law is present [38].

Entropy Indices and MSE

ApEn, ApEn(m, r), quantify the unpredictability of fluctuations in a time series, measuring the logarithmic probability that patterns of m observations will repeat themselves within predetermined tolerance thresholds r on the next incremental comparisons (m + 1). A time series containing many repetitive patterns has smaller entropy values than a time series which does not present such patterns. The sample entropy SampEn(m, r), is closely related to ApEn [43].

Costa et al. [34] introduced the so-called multiscale entropy MSE. The procedure considers a time series of N points and constructs consecutive coarse-grained time series $[y^{(\tau)}]$, as a function of the factor τ :

$$y_j^{(\tau)} = \frac{1}{\tau} \sum_{i=(j-1)\tau+1}^{j\tau} x_i \text{ for } 1 \leq j \leq \frac{N}{\tau}. \quad (1)$$

$[y^{(1)}]$ is the original time series, N/τ is the length of each coarse-grained time series.

An entropy measure is calculated for each sequence $[y^{(\tau)}]$ and plotted as a function of the scale factor τ . The MSE curves were estimated by means of ApEn (2, 0.15) and SampEn (2, 0.15). In this work, the slope of MSE curve with scale factors between 1 and 5 were estimated [31] and the values at scale factor 1 were considered the reference entropy values (ApEn and SampEn) in the statistical analyses.

The multiscale procedure distinguishes repetitive patterns as functions of different scales. Differences in the MSE index at different time scales reflect the regularity and structure of the time series (i.e. short vs. long range).

FHN Trial Group

Chair, Steering Committee: Klinger A; NIDDK: Eggers P, Briggs J, Hostetter T, Narva A, Star R; Centers for Medicare and Medicaid Services: Augustine B, Mohr P; Data Coordinating Center – Cleve-

land Clinic: Beck G (PI), Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, MacKrell J, Wiggins K, Sherer S, Weiss B; MRI Core – Ohio State University and Mt. Sinai Medical Center: Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M; Tran T, West J; Central Quality of Life Core – University of Pittsburgh: Unruh M; Keene R, Schlarb J; Central Holter Core – Toronto General Hospital: Chan C; McGrath-Chong M; Biospecimen Repository – Fisher BioServices: Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C; Data Safety and Monitoring Board: Eknayan G (Chair), Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E.

Daily Trial Clinical Sites – University of California San Francisco (UCSF)/Stanford Consortium: Chertow G (PI); UCSF and San Francisco Bay Area: James S, Chertow G, Tamura M, Hall Y, McCulloch C, Painter P, Gorodetskaya I, Tichy M, Humphreys M, Luan J, Escalada R, Rodriguez R; UC Davis and Sacramento Area: Depner T, Kaysen G, Suter M, Sonico J, Anderson S; El Camino Hospital and Satellite Health Care: Ting G, Schiller B, Coplon N, Doss S, Rogers J, Dominguez A, Atwal J, Lemus D; UCLA and Los Angeles Area: Rastogi A, Nissenson A, Goodman W, Salusky I, Schweitzer S, Rivas M, Smith M, Gayda P, Hernandez A, Rashid M; UCSD and San Diego Area: Mehta R, Pepas J, Bharti B, Nabali A, Manaster R, Mathew R, Shah S, Sanz G, Wei J; University of Texas, San Antonio: Ayus J, Achinger S, Gutierrez M; Renal Research Institute (RRI) New York Consortium: Levin N (PI); Bay W, Carter M, Geronemus R, Kuhlmann M, Handelmann G, Gotch F, Finkelstein F, Kimmel P, Lacson E, Ornt D, Greenwood R, Vassalotti J, Burrowes J; RRI New York City: Levin N, Kotanko P, Kaufman A, Winchester J, Meisels I, Raddbill B, Chang J, Fofie Y, Ramos R, Sergeyeva O, Callegari J, Arthur B, Tarallo M, Ulloa D, Apruzzese R; University of Western Ontario: Lindsay R, Suri R, Garg A, Bullas R, Mazzorato A; Wake Forest University School of Medicine: Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Coppley A; Vanderbilt University Medical Center: Schulman G, McLeroy S, Sika M, Leavell E; Barnes Jewish/Washington University: Miller B, Schussler R, Bardsley J, Skelton R.

References

- Chan CT, Greene T, Chertow GM, Klinger AS, Stokes JB, Beck GJ, Daugirdas JT, Kotanko P, Larive B, Levin NW, Mehta RL, Rocco M, Sanz J, Schiller BM, Yang PC, Rajagopalan S; Frequent Hemodialysis Network Trial Group: Determinants of left ventricular mass in patients on hemodialysis: frequent hemodialysis network (FHN) trials. *Circ Cardiovasc Imaging* 2012;5:251–261.
- London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. *J Am Soc Nephrol* 2001;12:2759–2767.
- Kayikcioglu M, Tumuklu M, Ozkahya M, Ozdogan O, Asci G, Duman S, Toz H, Can LH, Basci A, Ok E: The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. *Nephrol Dial Transplant* 2009;24:956–962.
- Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A, Dorhout Mees EJ: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. *Nephrol Dial Transplant* 1998;13:1489–1493.
- Reyes-Bahamonde J, Raimann JG, Thijssen S, Levin NW, Kotanko P: Fluid overload and inflammation – a vicious cycle. *Semin Dial* 2013;26:31–35.
- Akaishi M, Hiroe M, Hada Y, Suzuki M, Tsubakihara Y, Akizawa T; KRN321 Study Group: Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease. *J Cardiol* 2013;62:249–256.
- Mancusi C, Gerdtts E, De Simone G, Abdelhai YM, Lonnebakken MT, Boman K, Wachtell K, Dahlöf B, Devereux RB: Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study). *Blood Press* 2014;23:206–212.
- Sany D, Elsayy AE, Aziz A, Elshahawy Y, Ahmed H, Aref H, El Rahman MA: The value of serum FGF-23 as a cardiovascular marker in HD patients. *Saudi J Kidney Dis Transpl* 2014;25:44–52.
- Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators: Fibroblast growth factor-23 and cardiovascular events in CKD. *J Am Soc Nephrol* 2014;25:349–360.

- 10 Burton JO, Jefferies HJ, Selby NM, McIntyre CW: Hemodialysis-induced repetitive myocardial injury results in global and segmental reduction in systolic cardiac function. *Clin J Am Soc Nephrol* 2009;4:1925–1931.
- 11 Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW: Frequent hemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). *Clin J Am Soc Nephrol* 2011;6:1326–1332.
- 12 Raimann J, Liu L, Ulloa D, Kotanko P, Levin NW: Consequences of overhydration and the need for dry weight assessment. *Contrib Nephrol* 2008;161:99–107.
- 13 Sharma S, Joseph J, Chonchol M, Kaufman JS, Cheung AK, Rafeq Z, Smits G, Kendrick J; HOST Investigators: Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. *Clin Nephrol* 2013;80:313–321.
- 14 Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation* 2009;119:2545–2552.
- 15 Knap B, Večerić-Haler Ž, Benedik M, Buturović-Ponikvar J, Ponikvar R, Bren AF: Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis. *Ther Apher Dial* 2013;17:407–411.
- 16 Nishimura M, Tokoro T, Nishida M, Hashimoto T, Kobayashi H, Yamazaki S, Imai R, Okino K, Iwamoto N, Takahashi H, Ono T: Sympathetic overactivity and sudden cardiac death among hemodialysis patients with left ventricular hypertrophy. *Int J Cardiol* 2010;142:80–86.
- 17 Park J: Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system. *Cardiol Res Pract* 2012;2012:319432.
- 18 Goldberger AL: Non-linear dynamics for clinicians: chaos theory, fractals, and complexity at the bedside. *Lancet* 1996;347:1312–1314.
- 19 Iyengar N, Peng CK, Morin R, Goldberger AL, Lipsitz LA: Age-related alterations in the fractal scaling of cardiac interbeat interval dynamics. *Am J Physiol* 1996;271:R1078–R1084.
- 20 Bigger JT Jr, Steinman RC, Rolnitzky LM, Fleiss JL, Albrecht P, Cohen RJ: Power law behavior of RR-interval variability in healthy middle-aged persons, patients with recent acute myocardial infarction, and patients with heart transplants. *Circulation* 1996;93:2142–2151.
- 21 Ho KK, Moody GB, Peng CK, Mietus JE, Larson MG, Levy D, Goldberger AL: Predicting survival in heart failure case and control subjects by use of fully automated methods for deriving nonlinear and conventional indices of heart rate dynamics. *Circulation* 1997;96:842–848.
- 22 Fukuta H, Hayano J, Ishihara S, Sakata S, Ohte N, Takahashi H, Yokoya M, Toriyama T, Kawahara H, Yajima K, Kobayashi K, Kimura G: Prognostic value of nonlinear heart rate dynamics in hemodialysis patients with coronary artery disease. *Kidney Int* 2003;64:641–648.
- 23 Celik A, Melek M, Yuksek S, Onrat E, Avsar A: Cardiac autonomic dysfunction in hemodialysis patients: the value of heart rate turbulence. *Hemodial Int* 2011;15:193–199.
- 24 Suzuki M, Hiroshi T, Aoyama T, Tanaka M, Ishii H, Kishihara M, Iizuka N, Murohara T, Hayano J: Nonlinear measures of heart rate variability and mortality risk in hemodialysis patients. *Clin J Am Soc Nephrol* 2012;7:1454–1460.
- 25 Fukuta H, Hayano J, Ishihara S, Sakata S, Mukai S, Ohte N, Ojika K, Yagi K, Matsumoto H, Sohmiya S, Kimura G: Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. *Nephrol Dial Transplant* 2003;18:318–325.
- 26 Suri RS, Garg AX, Chertow GM, Levin NW, Rocco MV, Greene T, Beck GJ, Gassman JJ, Eggers PW, Star RA, Ornt DB, Klinger AS; Frequent Hemodialysis Network Trial Group: Frequent hemodialysis network (FHN) randomized trials: study design. *Kidney Int* 2007;71:349–359.
- 27 Wang Z, St-Onge MP, Lecumberri B, Pi-Sunyer FX, Heshka S, Wang J, Kotler DP, Gallagher D, Wielopolski L, Pierson RN Jr, Heymsfield SB: Body cell mass: model development and validation at the cellular level of body composition. *Am J Physiol Endocrinol Metab* 2004;286:E123–E128.
- 28 Raimann JG, Zhu F, Wang J, Thijssen S, Kuhlmann MK, Kotanko P, Levin NW, Kaysen GA: Comparison of fluid volume estimates in chronic hemodialysis patients by bioimpedance, direct isotopic, and dilution methods. *Kidney Int* 2014;85:898–908.
- 29 Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30:473–483.
- 30 Chen Z, Ivanov PCH, Hu K, Stanley HE: Effect of nonstationarities on detrended fluctuation analysis. *Phys Rev E Stat Nonlin Soft Matter Phys* 2002;65:041107.
- 31 Costa M, Goldberger AL, Peng CK: Multi-scale entropy analysis of biological signals. *Phys Rev E Stat Nonlin Soft Matter Phys* 2005;71:021906.
- 32 Bianchi A, Bontempi B, Cerutti S, Gianoglio P, Comi G, Natali Sora MG: Spectral analysis of heart rate variability signal and respiration in diabetic subjects. *Med Biol Eng Comput* 1990;28:205–211.
- 33 Pikkujämsä SM, Mäkilä TH, Sourander LB, Räihä JJ, Puukka P, Skyttä J, Peng CK, Goldberger AL, Huikuri HV: Cardiac interbeat interval dynamics from childhood to senescence: comparison of conventional and new measures based on fractals and chaos theory. *Circulation* 1999;100:393–399.
- 34 Costa M, Goldberger AL, Peng CK: Multi-scale entropy analysis of complex physiological time series. *Phys Rev Lett* 2002;89:068102.
- 35 Gaasch WH, Little WC: Assessment of left ventricular diastolic function and recognition of diastolic heart failure. *Circulation* 2007;116:591–593.
- 36 Lombardi F, Sandrone G, Mortara A, Torzillo D, La Rovere MT, Signorini MG, Cerutti S, Malliani A: Linear and nonlinear dynamics of heart rate variability after acute myocardial infarction with normal and reduced left ventricular ejection fraction. *Am J Cardiol* 1996;77:1283–1288.
- 37 Ferrario M, Moissl U, Garzotto F, Cruz DN, Clementi A, Brendolan A, Tetta C, Gatti E, Signorini MG, Cerutti S, Ronco C: Effects of fluid overload on heart rate variability in chronic kidney disease patients on hemodialysis. *BMC Nephrol* 2014;15:26.
- 38 Cerutti S, Esposti F, Ferrario M, Sassi R, Signorini MG: Long-term invariant parameters obtained from 24-h Holter recordings: a comparison between different analysis techniques. *Chaos* 2007;17:015108.
- 39 Huikuri HV, Mäkilä TH, Airaksinen KE, Seppänen T, Puukka P, Räihä JJ, Sourander LB: Power-law relationship of heart rate variability as a predictor of mortality in the elderly. *Circulation* 1998;97:2031–2036.
- 40 Lipsitz LA, Mietus J, Moody GB, Goldberger AL: Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope. *Circulation* 1990;81:1803–1810.
- 41 Kurata C, Uehara A, Sugi T, Ishikawa A, Fujita K, Yonemura K, Hishida A, Ishikawa K, Tawaraha K, Shouda S, Mikami T: Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. *Nephron* 2000;84:312–319.
- 42 Peng CK, Havlin S, Stanley HE, Goldberger AL: Quantification of scaling exponents and crossover phenomena in nonstationary heartbeat time series. *Chaos* 1995;5:82–87.
- 43 Richman JS, Moorman JR: Physiological time-series analysis using approximate entropy and sample entropy. *Am J Physiol Heart Circ Physiol* 2000;278:H2039–H2049.